Sarepta Therapeutics' stock dropped following the failure of Novartis' Phase 3 HARBOR study for myotonic dystrophy type 1 (DM1). While Sarepta is developing its own DM1 treatment, the rival's clinical stumble raises concerns about the broader therapeutic approach and market potential for such treatments, impacting investor sentiment for Sarepta.
Novartis AG announced that its Phase 3 HARBOR study for del-desiran in myotonic dystrophy type 1 (DM1) failed to meet its primary endpoint. This news directly impacted Sarepta Therapeutics (SRPT) because Sarepta is also developing an RNA-based therapy, SRP-1003, for DM1. While not a direct competitor's drug, the failure of a late-stage trial in the same disease area can cast a shadow over the entire therapeutic approach or the perceived difficulty of treating the condition, leading to a negative sentiment for other companies in the space. Short-term, SRPT's stock is down due to this perceived industry-wide setback. Long-term implications depend on Sarepta's own clinical trial data for SRP-1003, expected in H2 2026, which could differentiate its approach or confirm broader challenges. For traders, this presents a risk for SRPT as the market re-evaluates the DM1 treatment landscape.